Updated IDSA/ATS guidelines on management of adults with HAP and VAP

Document Type


Publication Date



Guidelines for the management of adults with hospital-acquired pneumonia (HAP) and ventilator-associated pneumonia (VAP) were recently published by the Infectious Diseases Society of America and the American Thoracic Society. For patients with suspected VAP or HAP, an empiric antimicrobial regimen that has activity against Staphylococcus aureus and Pseudomonas aeruginosa should be used. Empiric coverage for methicillin-resistant S aureus and dual antipseudomonal therapy are needed for patients with risk factors for antimicrobial resistance or for patients being treated in patient-care units demonstrating higher rates of resistance. The recommended duration of antimicrobial treatment for patients with VAP or HAP is 7 days. Pharmacists are in a key position to recommend de-escalation of antimicrobial therapy based on culture and sensitivity results and to ensure that patients are receiving the appropriate duration of therapy.

This document is currently not available here.